Thelansis

IgA Nephropathy Emerging Therapy and TPP Insights Thelansis’s “IgA Nephropathy Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . IgA Nephropathy Overview IgA Nephropathy is the most common primary glomerulonephritis, caused by mesangial deposition of galactose-deficient IgA1 immune complexes, triggering complement activation and progressive glomerular injury. It presents with recurrent hematuria, persistent microscopic hematuria, or proteinuria. Renal biopsy with immunofluorescence confirms diagnosis; proteinuria at or above 0.5g/day, hypertension, and reduced eGFR define high progression risk. Foundational therapy combines RAS blockade, SGLT2 inhibitors, and blood pressure optimization; targeted-release budesonide and spar...

IgA Nephropathy Emerging Therapy and TPP Insights Thelansis’s “IgA Nephropathy Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs Target Product Profiles Attributes and levels Ph...

IgA Nephropathy Emerging Therapy and TPP Insights Thelansis’s “IgA Nephropathy Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs Target Product Profiles Attributes an...

IgA Nephropathy Emerging Therapy Thelansis’s “IgA Nephropathy Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . IgA Nephropathy Overview IgA nephropathy (IgAN) is the most prevalent form of primary glomerulonephritis worldwide. The fundamental issue of this condition lies in the abnormal glycosylation of O-linked glycans (glycoproteins) within the hinge region of IgA1 throughout the body. Consequently, there are increased galactose-deficient IgA1 (GdIgA1) levels in the bloodstream, targeted by glycan-specific IgA and IgG autoantibodies. IgA, an antibody integral to mucosal immunity, occurs in two isotypes, namely IgA1 and IgA2. It can also exist as a dimeric structure known as secretory IgA. Plasma cells mainly...